SHARE THIS ARTICLE
Hymovis
Hymovis vs Hyalgan – Differences Explained
Nov 21, 2024
Proper joint movement is crucial for maintaining an active and healthy lifestyle. According to experts, the knee joint is the largest and most stressed joint in the body, playing a vital role in supporting body weight, movement, and balance.
For knee osteoarthritis patients, treatments like Hymovis and Hyalgan offer non-surgical options to alleviate pain and improve joint function. Both products are viscosupplements that inject hyaluronic acid into the affected joint, but they differ in composition, application, and duration of effect.
In this article, we will compare Hymovis vs Hyalgan, examining their differences, benefits, and suitability to help you make an informed decision about your knee health.
Key Takeaways
- Hymovis features high-molecular-weight hyaluronic acid for enhanced joint lubrication and extended pain relief, while Hyalgan uses low-molecular-weight hyaluronic acid for steady symptom improvement.
- Hymovis requires only two injections spaced a week apart, while Hyalgan involves a series of three to five weekly injections.
- Both treatments typically offer pain relief for up to six months, though Hymovis may provide longer-lasting benefits for some patients.
- Hymovis is ideal for those seeking a shorter treatment schedule, while Hyalgan may suit individuals who prefer a gradual approach or have mild to moderate symptoms.
About: Trusted by over 2,000+ global clients since 2014, Direct Doctor Supply has become a leading supplier of cosmetic, skincare, and orthopedic products for medical and aesthetic professionals. Direct Doctor Supply offers a wide range of authentic brand-name products at competitive wholesale prices, sourced from around the world.
Molecular Structure and Composition
Hymovis and Hyalgan both utilize hyaluronic acid (HA) to manage knee osteoarthritis, but their molecular structures set them apart. Hymovis features high-molecular-weight hyaluronic acid (HYADD®4), a unique formulation that provides superior joint lubrication and cushioning.[1] Its dense consistency enhances shock absorption and reduces friction, offering long-lasting relief and smoother knee movement.

On the other hand, Hyalgan uses low-molecular-weight hyaluronic acid to reduce inflammation and alleviate knee pain. Its lighter formulation supports joint movement and may help reduce friction within the knee. Those looking to order Hymovis online can find the product through Direct Doctor Supply, which supplies medical products for healthcare and clinical use.
Duration of Effects and Injection Protocols
Hymovis and Hyalgan both aim to reduce knee pain and improve mobility, but their injection protocols and duration of effect differ.
Hymovis offers a two-injection regimen, with each injection containing 3 mL of solution administered one week apart. Its high-molecular-weight hyaluronic acid is designed to support joint lubrication and cushioning, with symptom relief that may last several months. To minimize discomfort and swelling, patients should follow their healthcare provider’s post-treatment recommendations and avoid strenuous activities as advised.
In contrast, Hyalgan requires a series of injections administered over several weeks, with each dose containing 2 mL of solution. Its hyaluronic acid formulation is used to support pain relief and joint function, while the multi-injection regimen provides repeated treatment over the course of therapy. Patients should similarly follow post-injection instructions provided by their healthcare professional.
For those reviewing Hymovis vs Hyalgan, differences in injection schedules, formulations, and individual treatment response may be considered alongside the patient’s clinical needs and healthcare provider’s recommendations.
Side Effect Profiles and Clinical Outcomes
Hymovis and Hyalgan are generally well-tolerated viscosupplements, but like any medical treatment, they can cause mild side effects. These typically occur at the injection site and are temporary in nature. When comparing other viscosupplementation treatments (such as Hymovis vs Euflexxa), the side effect profiles are similarly mild, reflecting the overall safety of hyaluronic acid-based injections.

Patients may experience mild swelling, pain, or stiffness in the knee following the injection. Some individuals report redness or warmth around the injection site, but these symptoms usually resolve within a few days. Rare complications, such as infection or severe allergic reactions, are uncommon when administered by a qualified healthcare provider.
2026 Study Update: HYMOVIS® ONE Shows Sustained Clinical Improvement
A 2026 randomized, double-blind, multicenter study evaluated HYMOVIS® ONE in 347 patients with knee osteoarthritis. Following a single intra-articular injection, walking pain decreased by 65% at week 12 and 73% at week 26. Researchers also observed clinically significant improvements in stiffness, physical function, health-related quality of life, and other treatment outcomes. At 26 weeks, HYMOVIS® ONE was non-inferior to MONOVISC for pain relief, and both treatments were well tolerated. These findings provide recent evidence of sustained symptom and functional improvement following HYMOVIS® ONE treatment.[5]
Clinical Outcomes
Clinical studies on Hymovis have significantly reduced pain scores and improved cartilage volume and Type II collagen turnover. Specifically, a pivotal trial revealed a 34% reduction in WOMAC/VAS pain scores at six months. Long-term follow-up studies have also shown substantial improvements in pain, stiffness, and physical function.
Similarly, Hyalgan has demonstrated benefits in several clinical trials. Notably, a double-blind, placebo-controlled study reported pain relief lasting up to six months. Additionally, studies conducted in Asian populations and within multimodal treatment contexts supported improvements in pain and physical function. Reviewing the available evidence can help practitioners better understand the clinical differences between Hymovis vs Hyalgan.
Patient Satisfaction and Considerations for Treatment Selection
Selecting between Hymovis and Hyalgan depends on the patient’s lifestyle, medical history, and specific needs.

Hymovis suits individuals seeking a convenient treatment option with fewer injections. Its two-injection regimen over a week appeals to busy patients who want minimal disruption to their schedules. Additionally, its high-molecular-weight hyaluronic acid may offer extended relief, making it ideal for patients with advanced osteoarthritis or those prioritizing longer-lasting results.
Hyalgan, with its three-to-five weekly injection protocol, caters to individuals who prefer a gradual approach to symptom relief. This regimen may benefit older adults or patients with mild to moderate osteoarthritis who prefer steady improvement over time.
Patient Satisfaction with Hymovis
- Cou..: “Hymovis works great! No pain, soreness, or side effects. My left knee used to bother me most of the time, but after I had the two shots, all the pain/soreness was gone. The injections were effective for a full year. I am now going to get a second round. Highly recommended!”
Patient Satisfaction with Hyalgan
- Anonymous: ”Hyalgan injections have worked for me immensely! My first round of 3 lasted a year. I just started my second round as I had a flare-up. Some orthopedic surgeons feel no proof that it works and are convincing the insurance companies not to cover Hyalgan. They are saying it’s a placebo effect. I am living proof that it works for my osteoarthritis!”
Conclusion
Hymovis and Hyalgan are effective viscosupplements that cater to different patient needs for managing knee osteoarthritis. Hymovis’s two-injection protocol provides convenience and potentially longer-lasting relief, making it suitable for patients with busy lifestyles or advanced symptoms. Hyalgan’s multi-injection regimen offers a more gradual approach to symptom management, appealing to individuals who value steady improvement.
When considering Hymovis vs Hyalgan, discuss factors such as medical history, treatment preferences, and individual response with a qualified healthcare provider to determine the most appropriate approach for knee joint care.
FAQs
1. What is Hymovis used for?
Hymovis is an injectable hyaluronic acid treatment for knee osteoarthritis. It provides lubrication to the joint, reduces pain, and improves joint movement.
2. How does Hymovis work?
Hymovis contains a unique hyaluronan derivative called HYADD®4, which enhances joint lubrication and helps restore the viscoelastic properties of synovial fluid. This reduces friction in the knee joint, easing pain and improving mobility.
3. How long do the effects of Hymovis last?
The effects of Hymovis typically last up to six months. It provides long-lasting pain relief and improved joint function, which can benefit patients seeking fewer injections over time.
4. What are the possible side effects of Hymovis?
Common side effects of Hymovis may include temporary pain, swelling, or redness at the injection site. Serious side effects are rare, but you should consult your doctor if you experience unusual symptoms after the injection.
Citations
[1] Tiwari, Sanjay, and Pratap Bahadur. “Modified Hyaluronic Acid Based Materials for Biomedical Applications.” International Journal of Biological Macromolecules, vol. 121, Jan. 2019, pp. 556–71. doi:10.1016/j.ijbiomac.2018.10.049. Accessed 25 Sept. 2026.
[2] Knee Joint. Cleveland Clinic, 1 May 2024. https://my.clevelandclinic.org/health/body/24777-knee-joint.
[3] Galesso, D., I. Finelli, G. Paradossi, and D. Renier. “Viscoelastic Properties and Elastic Recovery of HYADD® 4 Hydrogel Compared to Crosslinked HA-Based Commercial Viscosupplements.” Osteoarthritis and Cartilage, vol. 20, 2012, p. S292. doi:10.1016/j.joca.2012.02.506.
[4] Kolarz, G., R. Kotz, and I. Hochmayer. “Long-Term Benefits and Repeated Treatment Cycles of Intra-Articular Sodium Hyaluronate (Hyalgan) in Patients with Osteoarthritis of the Knee.” Seminars in Arthritis and Rheumatism, vol. 32, no. 5, 2003, pp. 310–19. doi:10.1053/sarh.2002.50013.
[5] Ruosi, C., et al. “Single-Injection Hyaluronic Acid Treatment Demonstrates Non-Inferiority in the Relief of Symptomatic Knee Osteoarthritis: A Randomized Double-Blind, Multi-Center Controlled Study.” Osteoarthritis and Cartilage Open, vol. 8, no. 2, 5 Feb. 2026, p. 100752. https://doi.org/10.1016/j.ocarto.2026.100752. PubMed. Accessed 25 Sept. 2026.
Sourcing and accuracy for this article follow our Editorial policy: claims are cross-checked against clinical literature, regulatory filings, and manufacturer specifications before anything is published

